Mobile

A Randomized Double-Blind, Placebo- and Active-Control, Parallel-arm, Phase III Trial with Controlled Adjustment of Dose to Evaluate the Efficacy and Safety of CG5503 Prolonged-Release (PR) in Subject...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-005783-67

A Randomized Double-Blind, Placebo- and Active-Control, Parallel-arm, Phase III Trial with Controlled Adjustment of Dose to Evaluate the Efficacy and Safety of CG5503 Prolonged-Release (PR) in Subjects with Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of the trial is to evaluate the efficacy and safety of orally administered CG5503 PR (base) at doses of 100-250 mg twice daily in subjects with moderate to severe chronic pain from OA of the knee

Critère d'inclusion

  • Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee

Liens